Abstract
What's in a name? Terminology has the power to shape the ethical and regulatory debate surrounding commercially offered genomic testing. This article discusses the normative effects of naming and framing, and proposes that the medical frame, with its focus on the reduction of harm, should be used in the evaluation and regulation of predictive genomic testing.
Original language | Undefined/Unknown |
---|---|
Pages (from-to) | 63-65 |
Number of pages | 3 |
Journal | Trends in Molecular Medicine |
Volume | 20 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2014 |